Attendee search 

Colliers International Group Inc. (NASDAQ: CIGI; TSX: CIG) is a global leader in commercial real estate services with more than 16,300 professionals operating from 502 offices in 67 countries. With an enterprising culture and significant insider ownership, Colliers professionals provide a full range of services to real estate occupiers, owners and investors worldwide across a broad range of property types, including:

• Brokerage;
• Global corporate solutions;
• Investment sales and capital markets;
• Project management and workplace solutions;
• Property and asset management;
• Consulting, valuation and appraisal services; and,
• Customized research and thought leadership. 

Colliers International has been ranked among the top 100 outsourcing firms by the International Association of Outsourcing Professionals' Global Outsourcing for 10 consecutive years, more than any other real estate services firm.

Simplifying Clinical Research 

Boston Biotech Clinical Research (BBCR) is a strategic clinical innovation organization (SCIO) that offers simplified, customized approaches to planning and conducting clinical research. 
BBCR has a strong knowledge of drug safety, strategic planning and how to maximize the potential of early phase clinical research. 

BBCR helps biotech, pharmaceutical and device companies to deliver capital- and time-efficient clinical development programs – and thereby helps fulfil their product development. 

The innovative approach offered by BBCR facilitates: 
• Strategic clinical plan that, accelerate value creation from the earliest phase of clinical trials 
• Innovative simplified clinical research, using strategies that fully utilize available resources – meeting the requirements of investors, partners and regulators 
• Evidence-based trial strategies, helping to reduce risks and maximize the chances of successful outcomes 
• Design-focused trials that facilitate patients’ recruitment and retention, and cost-effective clinical research

Anavex™ Life Sciences Corp. is a clinical stage biopharmaceutical company engaged in the development of novel drug candidates to treat Alzheimer’s, CNS diseases and various types of cancer, which have significant unmet medical needs.

ANAVEX™ 2-73, the Company’s orally available drug candidate developed to treat Alzheimer’s through potential disease modification, has undergone an initial Phase 1 human clinical trial and was well tolerated in doses up to 55mg.  Results from pre-clinical studies indicate that ANAVEX 2-73 demonstrates anti-amnesic and neuroprotective properties.

A highly encouraging synergistic effect has also been observed between ANAVEX 2-73 and donepezil (Aricept®).  The combined therapeutics, referred to as “ANAVEX™ PLUS,” produced up to 80% greater reversal of memory loss in Alzheimer’s disease models versus when the drugs were used individually.

ANAVEX PLUS is believed to be a compelling commercial opportunity.  The clinical trial risk is lower because donepezil (Aricept®) is already on the market, with global sales of $4-billion annually.  Donepezil (Aricept®) is now generic and a patent application has been filed for ANAVEX PLUS which, if granted, would provide protection until 2033.

Headquartered in New York, Anavex is an American publicly traded corporation quoted as AVXL.

Eutropics is advancing personalized medicine by providing novel, predictive diagnostic tests that are uniquely accurate in guiding patient cancer treatments.

» Innovative leading cancer treatment response predictors

» Demonstrated medical utility in blood cancers

» CLIA certified tests for Acute Myeloid Leukemia

» Validated tests for Chronic Lymphocytic Leukemia

Launchpad Venture Group, a Boston-based angel investment group, provides funding and advice to early-stage companies. Launchpad looks for innovative, technology-driven startup companies addressing a significant market opportunity where our investment can make a difference. We introduce entrepreneurs to potential investors through business plan presentations at monthly meetings. Launchpad Venture Group consists of individual angel investor members interested in achieving superior returns by financing privately held companies at an early stage of development.

Harnessing the brain’s immune system to fight neurodegeneration.

CereSpir is leading the way with a completely novel approach to Alzheimer’s disease (AD) by reducing inflammation and increasing clearance of tissue debris in the brain as a potential first disease-modifying treatment targeting the very earliest stages of the disease.

CSP-1103, an orally delivered tablet, has undergone Phase 2 testing in people with Mild Cognitive Impairment (MCI). The Company aims to initiate Phase 3 trials in 2015. CSP-1103 is a novel, first-in-class, small molecule microglial modulator that protects neurons and other cells in the brain. CSP-1103 is a novel, first-in-class, small molecule microglial modulator that protects neurons and other cells in the brain.

engaged in the research, development, manufacturing and marketing of therapeutic solutions focused on patients’ needs. Sanofi has core strengths in diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health and Genzyme.

VentriNova is a regenerative medicine company focused on reversing cardiac damage by activation of intrinsic repair pathways to generate de novo heart muscle cells. VentriNova’s first generation product is a gene therapy that delivers a critical mitotic regulator to diseased heart tissue to stimulate proliferation of cardiac muscle cells.

• No technology on the market or in clinical development, including stem cell-based technologies and other regenerative medicine applications, has the ability to grow new heart muscle cells in the diseased heart.

• VentriNova’s pioneering science and technology is centered on development of biologic and small molecule regulators of the cyclin A2 gene – the key switch mediating heart cell division.

• VentriNova’s technology demonstrated in both small and large animals the ability to control the modulation (increased gene expression) of the cyclin A2 gene, therefore stimulating endogenous growth of new myocytes (heart muscle cells).

• VentriNova’s VN-100 technology is the conductor that orchestrates existing human heart
  cells to divide and regenerate themselves – a cellular function that is silenced in early human development.

Technology allows for a large quantity of active ingredient to be stored in a polymer matrix for a constant and slow targeted release. The active polymer is either embedded onto textile supports or on self adhesive multi layer long lasting patches or in particles in suspension in a solution. Products include pain relief devices (active textiles or patches), slimming devices, active foot care, mosquito control devices,...

We are able to have products lasting much longer because we can insert a large amount of actives in the device and we control the release kinetic. For instance, istead of having a 8 hour pain relief patch, we can obtain a reusable, washable patch equivalent lasting several weeks.

Rheumatology/ Orthopedics / Dermatology / Slimming / Parasite control

Long lasting active release / Constant release / Targeted area